Sleep-Related Eating Disorder (SRED): Evaluation and Management
For patients with suspected SRED, first identify and eliminate causative medications (especially zolpidem, other Z-drugs, and benzodiazepines), then screen for and treat underlying sleep disorders (particularly restless legs syndrome and obstructive sleep apnea), and if idiopathic or refractory, initiate topiramate 100-300 mg/day as first-line pharmacotherapy.
Clinical Recognition and Diagnosis
SRED is a non-REM parasomnia characterized by recurrent episodes of eating or drinking during arousals from sleep with partial or complete amnesia for the events 1. The diagnosis is primarily clinical and requires:
- Eating episodes occurring after sleep onset with consumption of unusual food combinations or non-food items
- Partial to complete amnesia for the nocturnal eating
- Adverse consequences including weight gain, dangerous food preparation activities, consumption of toxic substances, or metabolic complications 2
Key Diagnostic Steps
The evaluation should specifically assess 1, 2:
- Medication history: Document all psychoactive medications, particularly zolpidem (strongest association with aOR 5.98), triazolam, zopiclone, eszopiclone, quetiapine, and other sedative-hypnotics 3, 4
- Comorbid sleep disorders: Screen for restless legs syndrome, periodic limb movements, obstructive sleep apnea, and sleepwalking—these are the most common triggers 5, 6
- Psychiatric comorbidities: Evaluate for mood disorders, anxiety, and stress as contributing factors 4
- Pattern documentation: Frequency of episodes, types of foods consumed, timing relative to sleep onset, and any recalled awareness
Polysomnography is indicated when the diagnosis is uncertain or when screening suggests comorbid sleep-disordered breathing or movement disorders that require objective confirmation 1.
Management Algorithm
Step 1: Address Medication-Induced SRED
Immediately discontinue or taper offending agents, particularly:
- Zolpidem and other Z-drugs (highest risk, especially at maximum recommended doses) 3
- Benzodiazepines
- Sedating antidepressants and antipsychotics 4
This intervention alone may resolve SRED in medication-induced cases 2.
Step 2: Treat Underlying Sleep Disorders
For RLS-associated SRED: Initiate dopamine agonists (pramipexole is specifically recommended) 5. This addresses the sleep fragmentation that triggers eating episodes.
For sleepwalking-associated SRED: Use low-dose clonazepam 0.5-2.0 mg at bedtime 5.
For OSA-associated SRED: Treat with PAP therapy to eliminate arousals 1.
Step 3: Pharmacotherapy for Idiopathic or Refractory SRED
First-line: Topiramate 100-300 mg/day 5, 1. This is the most consistently effective medication for idiopathic SRED.
Alternative options 5:
- SSRIs (sertraline or others) at 20-30 mg/day
- Clonazepam 0.5-2.0 mg at bedtime (particularly if concurrent sleepwalking features)
Melatonin has shown benefit in recent case reports for NREM parasomnias including SRED 4.
Step 4: Non-Pharmacological Interventions
Implement sleep hygiene and lifestyle modifications 4:
- Regular sleep schedule with consistent bed and wake times
- Stress reduction techniques
- Avoid alcohol, particularly in evening hours
- Environmental safety measures: Remove dangerous items from kitchen access, lock cabinets containing toxic substances, consider door alarms
Important Clinical Considerations
Differential diagnosis: Distinguish SRED from night eating syndrome (NES), which occurs with full awareness and consciousness. NES patients remember their eating and typically consume food after evening meals or upon awakening, whereas SRED involves amnesia and occurs during partial arousals from sleep 6.
Monitoring requirements: Patients require follow-up 2-3 times yearly to assess symptom frequency, treatment efficacy, weight changes, and medication side effects 5. This is particularly important given the metabolic consequences and injury risk.
Medication combinations: Limited evidence exists for combination therapy. When monotherapy fails, consider adding topiramate to an SSRI or combining with treatment of underlying sleep disorders rather than using multiple psychotropic agents 5.
Common pitfall: Failing to recognize medication-induced SRED leads to unnecessary additional pharmacotherapy when simple discontinuation would suffice. Always review the medication list first 3, 2.
The evidence base for SRED treatment remains limited, with most recommendations derived from case series and small observational studies rather than randomized trials 2. However, the approach of eliminating triggers, treating comorbidities, and using topiramate for refractory cases represents the current standard based on available data 1, 5.